Pharma giants bag Lynparza EMA approval for metastatic breast cancer
Lynparza EMA approval : Pharma giants AstraZeneca and MSD have secured an expansion of the European Medical Agency's (EMA) approval for their poly ADP-ribose polymerase ... Read More
AstraZeneca’s Lynparza shows promising results in phase 3 ovarian cancer trial
AstraZeneca has reported significant findings from its phase 3 trial, SOLO-2, for its ovarian cancer drug Lynparza (olaparib), demonstrating considerable improvement in survival chances for ... Read More